• slide
  • slide

Loss of Exclusivity

In many cases, manufacturers of pharmaceuticals are still able to generate relevant product sales after expiry of patent and data exclusivity. Ecker + Ecker supports here with detailed prognoses and provides strategic advice.



  • Identification of eligible cases
  • Prognosis of price erosion
  • Prognosis of sales erosion depending on the rebate contract status
  • Prognosis of profitability of rebate contracts



Derivation and assessment of different scenarios such as:

  • Rebate contract strategy
  • Launch of own generics
  • Price strategy

Publications on Price Development


Please contact

Dr. Christof Ecker

Dr. Christof Ecker
Phone +49 (40) 41 33 081-13